Lonza Group Ltd
LO3A
Company Profile
Business description
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Contact
Muenchensteinerstrasse 38
BaselCH-4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
18,686
Stocks News & Analysis
stocks
The lessons behind the best performing stock over the last 80 years
4 factors that led to the incredible returns of Philip Morris.
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,089.90 | 7.80 | 0.10% |
| CAC 40 | 8,102.30 | 28.32 | 0.35% |
| DAX 40 | 23,308.30 | 153.73 | 0.66% |
| Dow JONES (US) | 41,488.56 | 353.07 | -0.84% |
| FTSE 100 | 8,689.55 | 9.26 | 0.11% |
| HKSE | 24,740.57 | 595.00 | 2.46% |
| NASDAQ | 17,490.94 | 317.72 | -1.78% |
| Nikkei 225 | 37,845.42 | 448.90 | 1.20% |
| NZX 50 Index | 12,076.85 | 89.29 | -0.73% |
| S&P 500 | 5,604.91 | 70.21 | -1.24% |
| S&P/ASX 200 | 7,860.40 | 6.30 | 0.08% |
| SSE Composite Index | 3,429.76 | 3.63 | 0.11% |